RNLX - Why Is Kidney-Disease Diagnostic Focused Renalytix Stock Trading Higher Today? | Benzinga
Thursday, Renalytix plc (NASDAQ:RNLX) announced that effective March 1, 2024, the United States Government has approved adding the company’s FDA de Novo Marketing authorized test, kidneyintelX.dkd, to its 10-year Governmentwide Acquisition Contract for early-stage kidney disease bioprognostic testing services.
Pricing for kidneyintelX.dkd is set at $950 per reportable result, the company noted in its SEC filing.
Effective through 2031 and offered through the General Services Administration, the contract covers laboratory testing services provided by any government healthcare facility, including the U.S. Veterans Administration, Department of Defense military branches.
In addition, National Government Services (NGS), a Medicare Administrative Contractor, is holding its ...